LTR Pharma Establishes Exclusive US Pharmacy Fulfilment Rights for Erectile Dysfunction Product, Shares Jump 22%

MT Newswires Live
Jun 11

LTR Pharma (ASX:LTP) executed a binding term sheet with Strive Specialties, establishing exclusive US pharmacy fulfilment rights for its intranasal erectile dysfunction treatment product ROXUS, according to a Thursday Australian bourse filing.

The term sheet provides access to a multi-state 503A pharmacy platform to support national pharmacy fulfilment.

The agreement has a two-year initial term from commercial launch, with annual autorenewal unless either party elects not to renew. The product will be supplied through a multi-channel strategy incorporating telehealth, pharmacy fulfilment, and healthcare provider networks.

Its shares soared 22% in recent trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10